Related references
Note: Only part of the references are listed.Unique TP53 neoantigen and the immune microenvironment in long-term survivors of Hepatocellular carcinoma
Huayu Yang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
BiTEs, DARTS, BiKEs and TriKEs-Are Antibody Based Therapies Changing the Future Treatment of AML?
Cecily Allen et al.
LIFE-BASEL (2021)
Application of CAR-T Cell Therapy beyond Oncology: Autoimmune Diseases and Viral Infections
Ekaterina Zmievskaya et al.
BIOMEDICINES (2021)
Targeting a neoantigen derived from a common TP53 mutation
Emily Han-Chung Hsiue et al.
SCIENCE (2021)
Low immunogenicity of common cancer hot spot mutations resulting in false immunogenic selection signals
Arne Claeys et al.
PLOS GENETICS (2021)
Adoptive Immunotherapy beyond CAR T-Cells
Aleksei Titov et al.
CANCERS (2021)
Bispecific antibodies targeting mutant RAS neoantigens
Jacqueline Douglass et al.
SCIENCE IMMUNOLOGY (2021)
Bispecific antibodies come to the aid of cancer immunotherapy
Ivano Amelio et al.
MOLECULAR ONCOLOGY (2021)
TP53 missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironment
Martino Maddalena et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer
Ai-Min Jiang et al.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES (2021)
P53 and The Immune Response: 40 Years of Exploration-A Plan for the Future
Arnold J. Levine
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
p53, cancer and the immune response
Julianne Blagih et al.
JOURNAL OF CELL SCIENCE (2020)
Advancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment
Aleksei Titov et al.
CANCERS (2020)
New Advances in Cell Microarray Technology to Expand Applications in Target Deconvolution and Off-Target Screening
Jim Freeth et al.
SLAS DISCOVERY (2020)
P53: A Guardian of Immunity Becomes Its Saboteur through Mutation
Arjelle Decasa Agupitan et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Therapeutic Editing of the TP53 Gene: Is CRISPR/Cas9 an Option?
Regina Mirgayazova et al.
GENES (2020)
Key Players in the Mutant p53 Team: Small Molecules, Gene Editing, Immunotherapy
Vitaly Chasov et al.
FRONTIERS IN ONCOLOGY (2020)
CAR-T efficacy: is conditioning the key?
Sattva S. Neelapu
BLOOD (2019)
Targeting mutant p53-expressing tumours with a T cell receptor-like antibody specific for a wild-type antigen
Lionel Low et al.
NATURE COMMUNICATIONS (2019)
Opportunities and Challenges for Antibodies against Intracellular Antigens
Xiaofeng Yang et al.
THERANOSTICS (2019)
Targeting the MHC Ligandome by Use of TCR-Like Antibodies
Lene Stokken Hoydahl et al.
ANTIBODIES (2019)
Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy
Juan C. Almagro et al.
FRONTIERS IN IMMUNOLOGY (2018)
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Ugur Sahin et al.
NATURE (2017)
Generation of murine tumor cell lines deficient in MHC molecule surface expression using the CRISPR/Cas9 system
Krishna Das et al.
PLOS ONE (2017)
Identification and Characterization of Neoantigens As Well As Respective Immune Responses in Cancer Patients
Eva Braeunlein et al.
FRONTIERS IN IMMUNOLOGY (2017)
Therapeutic Antibodies against Intracellular Tumor Antigens
Iva Trenevska et al.
FRONTIERS IN IMMUNOLOGY (2017)
PDL1 Regulation by p53 via miR-34
Maria Angelica Cortez et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
PDL1 Regulation by p53 via miR-34
Maria Angelica Cortez et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Ligand dependent restoration of human TLR3 signaling and death in p53 mutant cells
Daniel Menendez et al.
ONCOTARGET (2016)
ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells
Giovanna Bossi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Simplified protocol for clinical-grade tumor-infiltrating lymphocyte manufacturing with use of the Wave bioreactor
Marco Donia et al.
CYTOTHERAPY (2014)
Pathways of Antigen Processing
Janice S. Blum et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
Efficient Generation of Human iPSCs by a Synthetic Self-Replicative RNA
Naohisa Yoshioka et al.
CELL STEM CELL (2013)
p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells
Alexandre Iannello et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
MHC Class I Antigen Processing and Presenting Machinery: Organization, Function, and Defects in Tumor Cells
Patrizia Leone et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Mutational landscape and significance across 12 major cancer types
Cyriac Kandoth et al.
NATURE (2013)
T-Cell Receptor-Like Antibodies: Targeting the Intracellular Proteome Therapeutic Potential and Clinical Applications
Maya Cohen et al.
ANTIBODIES (2013)
T-cell-receptor-like antibodies - generation, function and applications
Rony Dahan et al.
EXPERT REVIEWS IN MOLECULAR MEDICINE (2012)
Overexpression of p53 protein in human tumors
Keiji Inoue et al.
MEDICAL MOLECULAR MORPHOLOGY (2012)
Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma
Paul A. Moore et al.
BLOOD (2011)
Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab
Dirk Nagorsen et al.
EXPERIMENTAL CELL RESEARCH (2011)
TCR-like Biomolecules Target Peptide/MHC Class I Complexes on the Surface of Infected and Cancerous Cells
Jon A. Weidanz et al.
INTERNATIONAL REVIEWS OF IMMUNOLOGY (2011)
Towards a systems understanding of MHC class I and MHC class II antigen presentation
Jacques Neefjes et al.
NATURE REVIEWS IMMUNOLOGY (2011)
Pilot Study of Sentinel-Node-Based Adoptive Immunotherapy in Advanced Colorectal Cancer
Mona Karlsson et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
The history of p53 A perfect example of the drawbacks of scientific paradigms
Thierry Soussi
EMBO REPORTS (2010)
Therapeutic antibodies: successes, limitations and hopes for the future
Patrick Chames et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers
Inge Marie Svane et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Human TCR-Binding affinity is governed by MHC class restriction
David K. Cole et al.
JOURNAL OF IMMUNOLOGY (2007)
Restoration of p53 function leads to tumour regression in vivo
Andrea Ventura et al.
NATURE (2007)
Stable, soluble T-cell receptor molecules for crystallization and therapeutics
JM Boulter et al.
PROTEIN ENGINEERING (2003)
Share Paper
